Spin trapping agent phenyl N-tert-butylnitrone protects against the onset of drug-induced insulin-dependent diabetes mellitus  by Tabatabaie, Tahereh et al.
FEBS Letters 407 (1997) 148-152 FEBS 18472 
Spin trapping agent phenyl TV-ter^-butylnitrone protects against the onset 
of drug-induced insulin-dependent diabetes mellitus 
Tahereh Tabatabaiea*, Yashige Kotakea, Gemma Wallisa, Jane M. Jacobb, Robert A. Floyda 
"Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, 825 Northeast, 13th Street, Oklahoma City, 
OK 73104, USA 
hDepartment of Anatomical Sciences, University of Oklahoma, Health Sciences Center, Oklahoma City, OK 73190, USA 
Received 27 January 1997; revised version received 27 February 1997 
Abstract Insulin-dependent diabetes mellitus is an autoimmune 
disease believed to be caused by an inflammatory process in the 
pancreas leading to selective destruction of the ß-cells. Cytokines 
and nitric oxide (NO) have been shown to be involved in this 
destruction. Phenyl /V-ferf-butylnitrone (PBN) has demonstrated 
protective effects against several pathological conditions includ-
ing ischemia-reperfusion injury and endotoxin-induced shock. 
We report here that PBN co-administration can prevent the 
onset of the STZ-induced diabetes in mice. PBN co-treatment 
inhibited the streptozotocin (STZ)-induced hyperglycemia, the 
elevation in the level of glycated hemoglobin and weight loss in 
the treated mice. Histological observations indicated destruction 
of ß-cells in the STZ-treated animals and its prevention by PBN 
co-treatment. EPR spin trapping experiments in the pancreas 
indicated the in vivo formation of NO in STZ-treated animals 
and its attenuation by PBN treatment. 
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1. Introduction 
Insulin-dependent diabetes mellitus (IDDM) is an autoim-
mune disease characterized by a local inflammatory reaction 
in and around the islets of Langerhans in the pancreas. This 
inflammatory response, also known as insulitis, is caused by 
infiltration of monocytes, macrophages, and T-lymphocytes 
with the ultimate consequence of selective destruction of the 
insulin secreting ß-cells in the pancreas [1]. Several lines of 
evidence point to the involvement of the pro-inflammatory 
cytokines in the pathogenesis of IDDM. Interleukin-1 (IL-
1), tumor necrosis factor-cc, interferon-y (IFN-y), and partic-
ularly the combination of these cytokines have been shown to 
impair ß-cell function and to be cytotoxic to ß-cells in vitro 
[1^4]. Non-obese diabetic (NOD) mice given antibodies to 
IFN-y and IL-6 showed reduced severity of insulitis and a 
lower incidence of autoimmune diabetes [5]. A soluble IL-1 
receptor was found to protect against diabetes in NOD mice 
[6] and an IL-1 receptor antagonist was shown to prevent the 
diabetogenic process elicited by the drug streptozotocin (STZ) 
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[7]. The free radical nitric oxide has also been implicated in 
the development of IDDM. STZ-induced islet destruction and 
hyperglycemia in mice was reduced by the nitric oxide syn-
thase (NOS) inhibitor L-NG-monomethylarginine [8]. Islets 
isolated from NOD mice were found to produce nitrite (an 
oxidation product of NO) in vitro [9]. Selective inhibition of 
the inducible isoform of NOS (iNOS) by aminoguanidine was 
shown to prevent the IL-1-mediated hyperglycemia and hypo-
insulinemia [10]. 
The compound phenyl Af-tert-butylnitrone (PBN), which 
was originally developed as a free radical trapping agent 
[11], has a variety of pharmacological effects. These effects 
include the protective action against the central nervous sys-
tem (CNS) damage brought about by ischemia-reperfusion 
[12,13], the reduction of the mortality caused by endotoxin-
induced septic shock [14,15], and the amelioration of the CNS 
damage associated with the HIV envelope protein gpl20 ad-
ministration in rat neonate model [16]. Recently, Miyajima 
and Ko take [14,15] have demonstrated that the protective 
effect of PBN in septic shock is likely due to the ability of 
this compound to inhibit the induction of iNOS. In this study 
we have investigated whether PBN co-administration can pre-
vent STZ-induced IDDM in a mouse model. In vivo genera-
tion of NO in the pancreas as a result of STZ administration 
and the possible effect of PBN on this phenomenon have also 
been studied using electron paramagnetic resonance (EPR) 
spectroscopy. 
2. Materials and methods 
Streptozotocin was obtained from Sigma Chemical Company (St. 
Louis, MO). PBN was obtained from OMRF Spin Trap Source 
(Oklahoma City, OK). /V-(dithiocarboxy) sarcosine, in an iron com-
plex form was a gift from Dr. T. Yoshimura, Institute for Life Sup-
port Technology, Yamagata, Japan. Other chemicals were obtained 
from Sigma Chemical Co. 
Balb/c mice (male, 6-8 weeks) from Charles-River (Indianapolis, 
IN) were randomly divided into four groups (five mice per group) 
and were given intraperitoneal (i.p.) injections for 5 consecutive 
days of the following reagents: STZ, 40 mg/kg (STZ group); STZ, 
40 mg/kg + PBN, 150 mg/kg (STZ+PBN group); PBN, 150 mg/kg 
(PBN group); and phosphate buffer saline (PBS group). STZ was 
dissolved in citrate buffer (pH 4.5) and was administered within 10 
min of dissolving. Injection volume for each treatment was 0.2 ml. 
Animals receiving PBN co-treatment were injected with this com-
pound 15 min prior to STZ treatment. This group of animals received 
one extra injection of PBN only (150 mg/kg) at day 6. At different 
time intervals after the treatments, tail tip blood was drawn and used 
for the measurements of blood glucose level or glycated hemoglobin. 
Blood glucose level was determined by the glucose oxidase kit ob-
tained from Sigma Chemical Co. Glycated hemoglobin (Hb A]) was 
measured using a kit from Sigma. 
For histological studies, anaesthetized mice were perfused with 4% 
paraformaldehyde and pancreata were removed and post-fixed for an 
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Fig. 1. Effect of PBN co-administration on STZ-induced hyperglycemia. Mice were treated with PBS ( ♦ ) ; PBN, 150 mg/kg (■) ; STZ, 40 mg/ 
kg ( A ) ; or STZ, 40 mg/kg + PBN, 150 mg/kg (•) for 5 consecutive days. Values are reported as mean±SD. 
additional day. The paraffin sections were stained with Gomori's al-
dehyde fuschin for the identification of pancreatic ß-cells [17]. 
For in vivo trapping of NO in the pancreas of the STZ-treated 
animals, mice were treated with a single dose of STZ (120 mg/kg, 
i.p.). Some animals received PBN pretreatment (300 mg/kg) 30 min 
prior to STZ injection. Five and one-half hours after STZ adminis-
tration, animals received an i.p. injection of the newly developed NO 
spin trap, iron complex of JV-(dithiocarboxy) sarcosine (Fe-DTCS, 80 
mg/kg) [18]. Mice were killed 30 min after receiving the spin trap, the 
pancreata were immediately removed and placed on the EPR tissue 
cell (Wilmad, Buena, NJ) and the EPR spectra were recorded using a 
Bruker 300 electron spin resonance spectrometer at room tempera-
ture. EPR parameters were as follows: receiver gain, 5.00X 105; mod-
ulation amplitude, 2.0 gauss; modulation frequency, 100 kHz. Statis-
tical analyses were performed by 1-way analysis of variance 
(ANOVA) followed by Students' 7-test. 
3. Results 
In order to determine whether PBN co-treatment would 
protect the animals against the diabetogenic action of STZ, 
the effect of such treatment was determined on several indices 
of diabetes, namely, blood glucose level, the level of glycated 
hemoglobin, the weights of the animals, and the pancreata 
Fig. 2. Effect of PBN co-administration on STZ-induced weight loss. Mice were treated with PBS ( ♦ ) ; PBN, 150 mg/kg (■) ; STZ, 40 mg/kg 
( A ) ; or STZ, 40 mg/kg + PBN, 150 mg/kg (•) for 5 consecutive days. Values are reported as mean ± SD. The positive or negative half of each 
error bar has been demonstrated. 
Fig. 3. Microscopic images of mouse pancreatic tissue. A: In STZ-
treated mice pancreatic islets, and the ß cells (dark cells) contained 
within those islets are virtually absent in pancreatic tissue. B: In an-
imals treated with a combination of STZ+PBN, pancreatic ß cells 
(dark cells) are found in morphologically normal appearing islet tis-
sue. Arrowheads indicate pancreatic islets. C: In PBN-treated ani-
mals, pancreatic ß cells remain intact. Magnification: 172X. 
histology. Mice treated with STZ demonstrated a progressive 
rise in the blood glucose concentration which reached a pla-
teau at ca. 450 mg/dl by 3 weeks post-treatment. The blood 
glucose level of the animals which received PBN co-treatment, 
however, stayed near normal throughout the experiment (Fig. 
1). The differences between the two groups (STZ vs. 
STZ+PBN) were statistically significant (P<0.05 at day 11, 
and P < 1 0 - 5 at day 17 and thereafter). Mice treated with 
either PBS or PBN displayed blood glucose levels within the 
normal range throughout the experiment. No statistically sig-
nificant differences were observed between the blood glucose 
levels of these two groups. 
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Table 1 
Effect of PBN co-administration on STZ-induced increase in % gly-
cated hemoglobin 
Treatment 
PBS 
PBN 
STZ 
STZ+PBN 
% Glycated hemoglobin" 
Day 30 Day 50 
4.2410.45 4.0310.22 
4.6210.22 3.9710.16 
9.1610.64 9.1010.76 
4.7910.46" 4.6310.28" 
"Values are reported as the mean 1 standard deviation, n = 5.**Values 
are significantly different (P<0.01) from STZ-treated group. 
The STZ-treated mice demonstrated increasingly elevated 
levels of glycated hemoglobin. PBN co-administration main-
tained the glycated hemoglobin level in the treated animals 
close to the control values. The level of glycated hemoglobin 
in the STZ+PBN group was not significantly different from 
the PBS group at 30 days following treatment (P = 0.88). At 
50 days, a small but statistically significant (P- 0.005) in-
crease in the glycated hemoglobin was observed in the 
STZ+PBN versus the PBS group. As expected, the mice re-
ceiving either PBS or PBN (without STZ) had low levels of 
glycated hemoglobin (Table 1). 
The STZ-treated animals demonstrated an initial weight 
loss followed by a weight gain the rate of which was signifi-
cantly lower than the control (PBS) group (Fig. 2). PBN, 
however, prevented the STZ-induced weight loss and the 
weights of the STZ+PBN group remained very similar to 
those of the control animals. The differences between the 
weights of the two groups were found to be statistically sig-
nificant by day 11 ( P < 0.001). Mice receiving PBN only 
showed a small but statistically significant decrease in their 
weights when compared to the PBS-treated mice for up to 
20 days after treatment (P < 0.05). The reason for such weight 
loss is yet to be determined. 
Histological inspection of pancreatic tissue in STZ-treated 
mice indicated that the pancreatic islets and ß-cells were de-
stroyed (Fig. 3A). In animals treated with a combination of 
CONTROL 
g = 2.04 
STZ /\ A 
STZ+PBN j k 
20 gauss 
Fig. 4. EPR spectra obtained in the pancreata of the STZ-treated 
mice and the effect of PBN co-treatment. Mice were treated with 
PBS (CONTROL); STZ, 120 mg/kg (STZ); and STZ, 120 mg/ 
kg+PBN, 300 mg/kg (STZ+PBN). See Section 2 for experimental 
details. 
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PBN+STZ, pancreatic integrity was visually maintained but 
the number of ß-cells within the islets appears to be slightly 
reduced (Fig. 3B) as compared to PBN control (Fig. 3C). It is 
clear that the STZ-induced destruction of the islets was pre-
vented in this tissue. 
In order to determine whether STZ administration would 
cause the formation of NO in the pancreas of the treated 
mice, animals were treated with the newly developed NO 
spin trap Fe-DTCS following a single high dose of STZ 
(120 mg/kg) and EPR spectra of the pancreata of the treated 
animals were recorded. The characteristic triplet signal due to 
nitrogen with a hyperfine splitting of 13.0 gauss (g=2.04) was 
evident in these tissues (Fig. 4). PBN co-administration was 
found to greatly attenuate this signal. No signal was observed 
in the control (PBS-treated) animals. 
4. Discussion 
In this study, we have demonstrated that PBN protects 
against the onset of IDDM in an STZ-induced model of the 
disease. We also demonstrate STZ-mediated in vivo genera-
tion of NO in the pancreas of the treated animals, and the 
inhibitory effect of PBN in this process. 
PBN co-treatment significantly reduced the extent of the 
STZ-induced hyperglycemia in mice. Animals in the 
STZ+PBN group displayed blood glucose levels only slightly 
elevated (Fig. 1), whereas the STZ group showed significantly 
high blood glucose levels. In agreement with the observed 
blood glucose concentrations throughout the experiment, the 
level of glycated hemoglobin (an index of chronic hyperglyce-
mia) was almost doubled in the STZ group (Table 1), how-
ever, animals that had been treated with STZ+PBN showed 
normal level (Table 1). 
Because of the lack of ability to uptake glucose in the tis-
sues such as skeletal muscle which require insulin for glucose 
entry into the cell, insulin-dependent diabetic patients use fat 
reservoirs and eventually proteins, as energy sources. This 
results in weight loss among insulin-dependent diabetic sub-
jects in the absence of insulin therapy. Thus weight loss as a 
function of STZ-treatment and the effect of PBN co-admin-
istration was investigated as yet another index of IDDM. The 
STZ-treated mice weighed significantly less than the control 
animals at all time points post-treatment (Fig. 2). The mean 
weight of the STZ+PBN group, however, stayed very close to 
that of the control group. PBN treatment per se resulted in a 
small but statistically significant weight loss when compared 
to the PBS group. In addition, PBN co-treatment preserved 
the morphological integrity of the pancreatic islet ß-cells as 
indicated by histological studies (Fig. 3A-C). 
All these data indicate that PBN can counteract the diabe-
togenic effect of STZ. STZ treatment has been shown to in-
duce the expression of the cytokine IL-1 since an IL-1 recep-
tor antagonist was found to protect against the STZ-induced 
hyperglycemia and insulitis [7]. Nitric oxide has also been 
implicated in the ß-cell destruction caused by STZ-treatment. 
Inhibition of NO generation by NOS inhibitors reduces the 
hyperglycemia and islet destruction associated with STZ-treat-
ment in mice [8]. IL-1 treatment has been shown to induce 
NO formation in rat isolated islets as detected by low temper-
ature EPR [19]. Using EPR spin trapping methodology, we 
have provided direct evidence that STZ administration to 
mice does indeed result in the formation of NO in the pan-
151 
créas (Fig. 4). Nitric oxide and its oxidation products are 
cytotoxic species believed to cause cell damage and death 
through inactivation of mitochondrial iron-sulfur containing 
enzymes and direct oxidation (by peroxynitrite) [20,21]. 
Previously, PBN has been shown to inhibit the induction of 
iNOS and hence prevent the mortality and morbidity associ-
ated with endotoxin treatment in a mouse septic shock model 
[14,15]. We have recently demonstrated that PBN prevents the 
NO formation in the CNS of treated rat neonates caused by 
HIV envelope protein gpl20 and counteracts the behavioral 
retardation associated with such treatment [16]. PBN treat-
ment caused a significant decrease in the level of NO formed 
in the pancreas as a result of STZ treatment in mice (Fig. 4). 
Taken together, these observations indicate that PBN may 
interfere with certain intracellular step(s) in the cytokine cas-
cade initiated via stimulation by extracellular cytokines such 
as IL-1. A major outcome of the cytokine cascade is over-
expression of iNOS and over-production of NO. Such mech-
anisms may also account for the protective action of PBN 
against STZ-induced IDDM. It remains to be determined 
whether the inhibitory effect of PBN on iNOS induction is 
related to the ability of this nitrone to trap reactive free rad-
icals. 
Experiments are underway to determine at what stage(s) of 
the pathway leading to iNOS induction and NO over-produc-
tion does PBN intervene. Such information should provide 
deeper insights into the mechanisms responsible for the devel-
opment of IDDM. Thus, in conclusion, the data presented 
here clearly indicate that PBN and possibly chemically related 
compounds have the potential of becoming strong investiga-
tive tools in the area of diabetes research. Furthermore, the 
data herein presented indicate that PBN and related com-
pounds can potentially serve as therapeutical agents in 
IDDM by intervening the onset of the disease in individuals 
with increased risk for developing this disease. 
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